Results 101 to 110 of about 6,419 (213)

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study

Journal of Infection and Public Health
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally.
Wei Yang, Weiting Zhang, Jing Zhou, Xinyue Ma, Changsong Wang, Mingyan Zhao, Kaijiang Yu   +6 more
doaj   +1 more source

In Vitro Screening of Anti-Viral and Virucidal Effects Against SARS-CoV-2 by Phenylamino-Phenoxy-Quinoline Derivatives: An Integrative Computational Approach [PDF]

This study investigated the binding interactions between three groups of 2,4-disubstituted phenylamino-phenoxyquinoline derivatives 1-3(a-d) and four readily available drugs (ritonavir, ensitrelvir, nirmatrelvir, and paxlovid) with severe acute ...
Baicharoen, Apisara, Jittmittraphap, Akanitt, Jityuti, Benchawan, Kuno, Mayuso, Leaungwutiwong, Pornsawan, Makarasen, Arthit, Ngueanngam, Natchaphon, Patnin, Suwicha, Techasakul, Supanna, Vijitphan, Pongsit   +9 more
core   +1 more source

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +1 more source

Yi-Qing Oral Solution and Paxlovid combination for COVID-19: Efficacy and safety in a randomized controlled trial

Traditional Medicine and Modern Medicine
Background: The COVID-19 pandemic has exerted a significant social burden worldwide. Traditional Chinese medicine has emerged as a vital role in the clinical management of COVID-19.
Maimaititusun Yalikun, Xi Huang, Xueyi Zhu, Yuxue Cao, Jiming Zhang, Xin Ma, Jindong Hua, Jiaqi Liu, Xianjun Sun, Wenjing Du, Lingwen Kong, YanBo Ren, Hongli Xue, Baojun Liu, Yuanhao Zhang, Yang Lei, Zhen Gao, Weiyi Gong, Jingcheng Dong   +18 more
doaj   +1 more source

Computational molecular modeling of Paxlovid binding

, 2022
Computational binding modeling of the drug Paxlovid to the 3CL-protease of SARS-Cov-2 is presented. Paxlovid contains 2 molecule ingredients: Nirmatrelvir and Ritonavir. This is a detailed distributional analysis using docking of both small molecules, to the target protease and to the CYP 3A4 liver enzyme.
openaire   +1 more source

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China

Infection and Drug Resistance
Wei Yang,1,* Yahui Peng,1,* Changsong Wang,1,* Hongliu Cai,2 Lina Zhang,3 Jun Xu,2 Yongjie Wang,4 Maonan Wang,4 Mingyan Zhao,1 Kaijiang Yu1 1Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University ...
Yang W, Peng Y, Wang C, Cai H, Zhang L, Xu J, Wang Y, Wang M, Zhao M, Yu K   +9 more
doaj  

COVID-19 rebound after Paxlovid treatment [PDF]

Distributed via the CDC Health Alert NetworkMay 24, 2022, 9:00 AM ETCDCHAN-0467The Centers for Disease Control and Prevention (CDC) is issuing this Health Alert Network (HAN) Health Advisory to update healthcare providers, public health departments, and ...

core  

Nirmatrelvir: from discovery to modern and alternative synthetic approaches [PDF]

The global urgency in response to the COVID-19 pandemic has catalyzed extensive research into discovering efficacious antiviral compounds against SARS-CoV-2.
Alessandra Silvani, Andrea Citarella, Daniele Passarella, Francesco Migliano, Michela Galli, Valerio Fasano   +5 more
core   +1 more source

The path to Paxlovid

C&EN Global Enterprise, 2022
openaire   +2 more sources

Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients

Scientific Reports
This retrospective cross-sectional study aims to evaluate the safety, tolerability, and adherence of patients prescribed Nirmatrelvir-ritonavir (Paxlovid) in outpatient settings, focusing on its use in managing category 2 COVID-19 patients across three ...
Zahirah Zaharuddin, Nur Sabiha Md Hussin, Mahmathi Karuppannan   +2 more
doaj   +1 more source